Prot #CA-4948-102: A Phase 1/2a, Open-label Dose Escalation and Cohort Expansion Study of Orally Administered ca-4948 (IRAK4I) as a Monotherapy in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination with Azacitidine or